### 2.2.1 In vitro / physicochemical data

A literature search was performed to collect available information on physicochemical properties of montelukast. The obtained information from literature is summarized in the table below and is used for model building.

| **Parameter**   | **Unit**    | **Value (reference)** | **Description**                                  |
| :-------------- | ----------- | ----------------------------------- | ------------------------------------------------ |
| MW              | g/mol       | 586.2 ([Marzolini 2017](#5-references)) | Molecular weight                                 |
| pKa             |             | 4.4 ([Marzolini 2017](#5-references)) | Acid dissociation constant                   |
| Solubility (pH) | mg/mL       | 8.2E-06 (7) ([Drugbank](#5-references)) | Solubility                                       |
| logP            |             | 7.90 ([Marzolini 2017](#5-references)) | Partition coefficient between octanol and water  |
| fu              |             | 0.0018 ([Marzolini 2017](#5-references)) | Fraction unbound                                 |
| fe**   |          | <0.002 ([Marzolini 2017](#5-references)) | fraction of dose excreted unchanged in urine |
| CYP3A4-CLint | µl/min/pmol | 1.8 ([Marzolini 2017](#5-references)) | Cytochrome-P450 3A4 mediated intrinsic clearance |
| CYP3A5-CLint | µl/min/pmol | 1.8 ([Marzolini 2017](#5-references)) | Cytochrome-P450 3A5 mediated intrinsic clearance |
| CYP2C8-CLint | µl/min/pmol | 3.6 ([Marzolini 2017](#5-references)) | Cytochrome-P450 2C8 mediated intrinsic clearance |
| CYP2C9-CLint | µl/min/pmol | 0.48 ([Marzolini 2017](#5-references)) | Cytochrome-P450 2C9 mediated intrinsic clearance |

** fe was matched by modeling unchanged renal excretion in PK-Sim as glomerular filtration (GF)

### 2.2.2 Clinical data

A literature search was performed to collect available clinical data on montelukast PK in adults. 

The following publications were found in adults for model building and evaluation:

| Publication                       | Study description                                            |
| :-------------------------------- | :----------------------------------------------------------- |
| [Cheng 1996](#5-references) | Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females |
| [Fey 2014](#5-references) | Bioequivalence of two formulations of montelukast sodium 4 mg oral granules in healthy adults |
| [Knorr 2000](#5-references) | Montelukast adult (10-mg film-coated tablet) and pediatric (5-mg chewable tablet) dose selections |
| [Zhao 1997](#5-references) | Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers |


